Evidence map›Paper›PMID 36578868›Full record

ArticleWorld journal of diabetes2022

Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia.

Amir Bashkin, Mona Shehadeh, Lina Shbita, Kamil Namoura, Ronza Haiek, Elena Kuyantseva, Yousef Boulos, Orly Yakir, Etty Kruzel-Davila

Open access · diamondAbstract read
In one paragraph

Article in World journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Amir BashkinDepartment of Diabetes, Endocrinology, and Metabolism, Galilee Medical Center, Nahariya 2210001, Israel.
Mona ShehadehAzrieli Faculty of Medicine, Bar-Ilan University, Zefat 1311502, Israel.
Lina ShbitaAzrieli Faculty of Medicine, Bar-Ilan University, Zefat 1311502, Israel.
Kamil NamouraInternal Medicine A, Galilee Medical Center, Nahariya 2210001, Israel.
Ronza HaiekDepartment of Diabetes, Endocrinology, and Metabolism, Galilee Medical Center, Nahariya 2210001, Israel.
Elena KuyantsevaDepartment of Diabetes, Endocrinology, and Metabolism, Galilee Medical Center, Nahariya 2210001, Israel.
Yousef BoulosDepartment of Diabetes, Endocrinology, and Metabolism, Galilee Medical Center, Nahariya 2210001, Israel.
Orly YakirStatistical Analysis Division, Galilee Medical Center, Nahariya 2210001, Israel.
Etty Kruzel-DavilaAzrieli Faculty of Medicine, Bar-Ilan University, Zefat 1311502, Israel.
Bar-Ilan University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes mellitus is considered a leading contributor to severe coronavirus disease 2019 (COVID-19).

aimTo characterize differences between hospitalized diabetic patients with

methodsThis case-control study included 209 patients with type 2 diabetic mellitus hospitalized at the Galilee Medical Center (Nahariya, Israel) and recruited between September 2020 and May 2021, 65 patients with COVID-19 infection in dedicated wards and 144 COVID-19-negative patients in internal medicine wards hospitalized due to other reasons. Clinical parameters - including age, type of antiglycemic medications, presence of retinopathy, smoking history, body mass index (BMI), glycosylated hemoglobin, maximum neutrophil:lymphocyte ratio (NLR

resultsCOVID-19-negative patients were older (63.9 ± 9.9

conclusionModerate-range albuminuria in COVID-19-positive diabetic patients with CKD II is associated with less severe COVID-19. Further studies should explore this potential biomarker for risk of COVID-19-related deterioration and early interventions.

Indexed as

AlbuminuriaChronic kidney diseaseCOVID-19Diabetes mellitusImmunomodulationSeverity

Identifiers

PMID36578868
PMCPMC9791569
OpenAlexW4311418207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.